have been used to demonstrate fibrovascular ingrowth in orbital hydroxyapatite implants. MRI with intravenous gadolinium is thought to provide the most accurate non-invasive estimate of vascularisation of the implant. 6 We report the clinical and MRI results of a series of consecutive patients who underwent either primary or secondary synthetic hydroxyapatite orbital implantation.
Method
Twelve consecutive patients who had synthetic (FCI) hydroxyapatite spheres ranging in diameter between 16 and 22 mm implanted in 1995 were evaluated at least 9 months after implantation. The indications for implantation and ages of these patients are detailed in Table 1 . Surgery was performed by one surgeon (G.T.F.).
The surgical technique for insertion of hydroxyapatite implants has been described previously. ! Some aspects deserve special mention. During insertion the im p lant was covered with plastic, which allowed the implant Patients were followed-up regularly. All patients had a clinical assessment at least 9 months after surgery.
Patients were asked about their subjective impressions of the cosmetic result of surgery. MRI of the implant was performed at least 9 months after surgery using Tl scanner (Siemens, Erlangen, Germany) using the head coil. The position of the hydroxyapatite implant and enhancement after contrast injection were noted.
Results
Six male patients and 6 female patients, ranging in age from 5 to 71 years had synthetic (FeI) hydroxyapatite orbital implants. Six patients had primary orbital implants at the time of enucleation and 6 patients had secondary implants (Table 1) . One patient developed marked conjunctival chemosis, requiring temporary suture closure of the lids for 1 week. All 12 patients had good post operative volume augmentation and implant stability. No Therefore, MRI was carried out in 8 patients.
MRI with intravenous gadolinium, using coronal and axial views, demonstrated diffuse inhomogeneous (non uniform) enhancement in 3 of the primary orbital implants (Fig. 1) . One patient with a primary implant had a large area of poor enhancement posteromedially.
Moderate to large areas of non-enhancement occurred in all the patients in the secondary implantation group. The extent and site of those areas were variable (Figs. 2, 3 ). 
Discussion
Synthetic FCI hydroxyapatite orbital implants are less expensive than the coral hydroxyapatite implant and are thought to be a satisfactory alternative. The synthetic orbital implants have been reported to give good homogeneous vascularisation within 4 months of surgery. 8 Some surgeons assume vascularisation of these implants after 6-9 months and are happy to drill and peg the implants without prior MRI scanning. In our small consecutive series of 12 patients, all had good clinical results with the synthetic implant and no patient requested drilling with peg insertion. However, in 5 of 8 patients MRI scanning with gadolinium revealed moderate to large areas of poor enhancement within the implant more than 9 months after implantation. MRI scanning with intravenous gadolinium is considered to be a good non-invasive method for evaluating vascularisation of hydroxyapatite implants. It is considered superior to technetium bone scanning, CT, colour Doppler imaging and B-mode ultrasonography. 6 , 7
Patients in this study were scanned irrespective of the likelihood of drilling and peg insertion. Although the clinical results were excellent, the very variable vascularisation of these implants was disappointing. It is not clear from this study why a greater percentage of the patients who had secondary implants had significant areas of poor vascularisation. Vascular changes occurring in the orbit following previous enucleation and differences in surgery (more difficulty isolating recti muscles in secondary implantation) may contribute to this. However, one patient in the primary implantation group had a large area of poor vascularisation. We therefore feel that it is more likely that poor vascularisation is occurring secondary to poor interconnecting pores within the implant. A larger series may show no difference between the primary and secondary hydroxyapatite implant vascularisation.
